Presented by: Andrew Cleek, PsyD
Presentation title: NYS Medicaid Reform: How Will Medicaid Transformation Affect Access & Quality to Care for Patients with HIV, HCV, and Drug Dependence
New York State is undergoing the largest change in the way it pays for public sector health care in decades. The presenters will discuss how the introduction of Health Homes, Delivery System Reform Incentive Payment (DSRIP), the Behavioral Health Managed Care Transition, and Value Based Payments are transforming care for individuals with HIV, HCV and behavioral health conditions.
Dr. Andrew Cleek oversees community partnerships and co-directs both New York State’s Community and Managed Care Technical Assistance Centers (CTAC and MCTAC) in his role as the McSilver Institute’s Executive Officer. Dr. Cleek was the founding director of the Urban Institute for Behavioral Health (UIBH), which was a unique partnership of behavioral health providers dedicated to the implementation of evidence-based practices, integrated primary and behavioral healthcare, and system transformation. Under Dr. Cleek’s leadership, UIBH became an incubator in which pilot projects were developed and brought to scale across New York City and State. Dr. Cleek regularly presents at local and national conferences and is the co-author of widely-used curricula including “Wellness Self-Management” and “Knowledge Empowers You (KEY).” Dr. Cleek also holds an appointment as a Research Assistant Professor at the New York University School of Medicine.
Presented by: Lisa Bowleg, PhD
Presentation title: It’s All in the Mix: How Mixed Methods Enhance (and Complicate) HIV Prevention Research
Mixed methods research is a distinct methodological approach that capitalizes on the advantages of qualitative and quantitative methods in a single study. Although interest in mixed methods is flourishing in the behavioral and social sciences, researchers interested in conducting mixed methods studies face numerous challenges—the lack of formal training in qualitative and mixed methods research, chief among them. Using examples from mixed methods behavioral HIV prevention research with Black heterosexual men as a foundation, this presentation will: (1) provide an overview of mixed methods and some mixed methods designs; (2) consider why, when and how researchers might use mixed methods; (3) emphasize “the mix” and its challenges; and (4) highlight how to build mixed methods knowledge and capacity.
Dr. Bowleg’s research focuses on: (1) the effects of individual-level and social-structural factors (e.g., unemployment, incarceration, racial discrimination) and resilience on Black men’s HIV sexual risk and protective behaviors; (2) intersectionality; and (3) experiences of intersectionality-related stress and resilience in Black, lesbian, gay, bisexual and transgender people. She is the joint-Principal Investigator (PI) with Dr. Anita Raj, UCSD of a 2012 NIH/NIMH-funded RO1 (1 R01 MH096657 – 01) to evaluate MEN Count, a housing and employment case management HIV prevention intervention for Black heterosexual men. Dr. Bowleg is also the PI of MENHOOD, a 2012 NIH/NIMH-funded R01 (1 R01 HD074451-01) to test a conceptual model of individual and neighborhood-level social-structural stressors and resilience on Black men’s sexual HIV risk and protective behaviors. REPRESENT, her 2007 NIH/NICHD-funded R01 (1 R01 HD054319-01), examined the effects of masculinity ideologies, sexual scripts and social-structural factors on Black heterosexual men’s sexual risk behaviors. Dr. Bowleg is a member of the DC Developmental Center for AIDS Research (CFAR) and an editorial board member of the Journal of Mixed Methods, Journal of Sex Research, Cultural Diversity and Minority Psychology, and LGBT Health. She is the recipient of the 2014 Psychology and AIDS Distinguished Leadership Award from the American Psychological Association.
Presented by: Charles Cleland, PhD
Presentation title: An Introduction to R: Get Started and See the Possibilities
An introduction to R, a mature, open-source platform for statistical computing. The unique advantages of R will be described, and essentials of data import & export, management, visualization, and common statistical analysis will be demonstrated.
Charles Cleland is a quantitative psychologist and biostatistician with more than ten years of experience in the field of public health research. His methodological interests include longitudinal data analysis, meta-analysis, respondent driven sampling, and multilevel modeling. His substantive research interests include health disparities, particularly in the areas of substance use and infectious disease.
Presented by: David Perlman, MD
Presentation title: Conceptualizing Care Continua: Lessons from HIV, Hepatitis C, and Tuberculosis -- Implications for the Development of Improved Care and Prevention Continua
The continuum construct is now a formal part of public health evaluation systems for HIV, and is increasingly used in public health and the medical literature. Issues with the comparability and optimal design of care continuum models have been raised, their methodologic and theoretic underpinnings, scope of focus, and modes of analysis have been under-addressed, including their use to assess intervention impact. Lessons learned from the application of continuum models to HIV and other conditions can inform the development of more comprehensive, informative and standardized care and prevention continua for their use as clinical program, public health and research tools.
David Perlman has over 20 years’ experience in HIV, HCV, TB and STIs and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, and committees within the ACTG, the NYS DOH AIDS Institute, and the NYC DOMH. Dr. Perlman’s earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB and HIV/TB care continuum. Dr. Perlman’s recent work has focused on studies of barriers and facilitators of HIV and HCV testing and care among racial and ethnic minorities, high risk heterosexuals, and people who use drugs, and more broadly on studies of strategies to improve HIV and HIV/HCV care continua and prevention programming for these populations.
Presented by: Hannah Cooper, Mark Hatzenbuehler & David Perlman
Presentation title: Mini-Conference on Structural Variables
The health of individuals and populations is influenced by a multitude of factors, at the individual level and at other levels. Yet knowing this, and despite calls for more attention to social determinants of health, many analyses nonetheless primarily focus on individual-level factors, and fail to formally examine the context, place and a wide range of measured and measurable place-related structural factors. This mini-conference, through special presentations and a facilitated audience and panel discussion, will provide an introduction to the rationale for the study of structural variables, their relation to health outcomes and to intervention development, consider relevant data sources and analytic considerations, and highlight two presentations of structural-level analyses relevant to the work of CDUHR and other investigators. The intent of the program is to inform current and future work by CDUHR-affiliated and other investigators.
- David Perlman, MD – Director, CDUHR Infectious Disease Epidemiology & Theory Core; Professor of Medicine, Icahn School of Medicine at Mount Sinai; Chief, Infectious Diseases, Mount Sinai Beth Israel – Introduction to Structural Variables: What They Are, Why We Care, How to Use in Studies
- Mark Hatzenbuehler, PhD – Associate Professor, Mailman School of Public Health at Columbia University – Structural Stigma and Sexual Orientation Health Disparities: Measurement, Methods, and Challenges
- Hannah Cooper, ScD – Associate Professor, Rollins School of Public Health at Emory University – Public Housing Relocations and Relocators’ Vulnerability to HIV: A Structural Approach
Facilitated Discussion Panelists:
- David Perlman, Mark Hatzenbuehler, and Hannah Cooper
- Charles Cleland, PhD – Associate Director, Transdisciplinary Research Methods Core; Senior Biostatistician, Rory Meyers College of Nursing at NYU
Presented by: Brandon DL Marshall, PhD
Presentation title: Using Microsimulation to Evaluate HIV Prevention and Treatment Strategies that Reduce Disparities and Maximize Impact
Dr. Marshall is the Manning Assistant Professor of Epidemiology at Brown University. His research interests focus on substance use epidemiology and examining the social, environmental, and structural determinants of health of drug-using populations. His work seeks to inform public health and policy interventions that improve the health of drug users. He is also interested in applying complex systems methods to examine factors that perpetuate HIV transmission in drug-using populations.
Presented by: Sarah Feldstein Ewing, PhD & Emily Merz, PhD
Presentation title: Developmental Cognitive Neuroscience of Adolescent Mental Health and Risk-Taking Behaviors: Implications for Assessment and Intervention
Sarah Feldstein Ewing, PhD, will discuss the neural and cognitive factors that influence adolescents’ decision-making around sex and their behaviorally co-occurring risk behaviors including substance use.
Dr. Feldstein Ewing is Professor in Child and Adolescent Psychiatry at OHSU and a licensed clinical child psychologist who utilizes a variety of evidence-based approaches to prevent and intervene with adolescent health risk behavior, including alcohol use, cannabis use, and HIV/AIDS risk behavior. She has developed a highly-innovative NIH-funded line of translational research evaluating the connection between basic biological mechanisms (e.g., functional brain activation, brain structure, genetic factors) and youth health risk behavior (e.g., clinical symptoms, HIV risk behaviors, treatment outcomes). She has conducted several NIH-funded, large-scale clinical trials with at-risk adolescents to evaluate the developmental fit and treatment outcomes for motivational interviewing, behavioral skills training, cognitive behavioral approaches, mindfulness and contingency management.
Emily Merz, PhD, will discuss NIMH’s Research Domain Criteria (RDoC) initiative and its implications for studying child and adolescent health behaviors with illustrations from her ongoing research. RDoC is a translational research framework designed to integrate many levels of information (e.g., genomics, neural circuits, physiology, self-report) to lead to a more comprehensive understanding of the dimensions of functioning underlying the full range of human behavior and to inform future therapeutic and preventive interventions.
Dr. Emily Merz is a postdoctoral fellow at the Columbia University Medical Center, working primarily with Dr. Kimberly Noble. She attained her PhD in clinical and developmental psychology from the University of Pittsburgh in August 2012. Her work is focused on examining the neurobiological mechanisms through which early adversity, particularly poverty, alters social-emotional development, leading to an increased risk for psychopathology in children and adolescents.
Feldstein Ewing SW, Ryman SG, Gillman AS, Weiland BJ, Thayer RE, Bryan AD (2016). Developmental cognitive neuroscience of adolescent sexual risk and alcohol use. AIDS and Behavior, 20 (Suppl 1), S97-S108. doi: 10.1007/s10461-015-1155-2.
Feldstein Ewing SW, Tapert SF, Molina BSG (2016). Uniting adolescent neuroimaging and treatment research: Recommendations in pursuit of improved integration. Neuroscience and Biobehavioral Reviews, 62, 109-114. doi: 10.1016/j.neubiorev.2015.12.011.
Goldstein AB, Morris SE. (2016). Reconceptualizing prevention: Commentary on “conducting psychopathology prevention research in the RDoC era”. Clinical Psychology: Science and Practice, 23 (1), 105-108. doi: 10.1111/cpsp.12143.
Presented by: Gkikas Magiorkinis, MD, Msc, PhD, Path
Presentation title: Evolutionary Epidemiology of Viral Infections and Applications to Public Health Research
This seminar will provide an outline and describe basic concepts on how evolutionary epidemiology works by exploiting the phenomenon of viral evolution with the methods of phylogenetics, phylodynamics and phylogeography. It will also show how modern technologies of reading DNA sequences have revolutionised the field of viral genomics. Finally, it will provide practical examples of these methods with public health applications.
Gkikas Magiorkinis is a Senior Clinical Fellow and a University Research Lecturer at the University of Oxford, and Consultant in Medical Virology in Public Health England, Colindale. Dr. Magiokinis has published more than 50 papers and focuses on translating viral evolution in biomedical applications. Most notably his research has revealed the hidden dynamics on how HCV and HIV spread around the world, as well as among PWIDs. Dr. Magiokinis is funded by the Medical Research Council to study the pathophysiology of ancient retroviral infections of the human germline.
Presented by: Julie Netherland, PhD
Presentation title: Bridging the Research Policy Divide: The Role of Researchers in Drug Policy Reform
The divide between research and policy can be vast, especially for a controversial issue, such as drugs, where stigma and ideology often trump science. But now more than ever, solid evidence is needed to guide the nation’s drug policies. This talk offers a behind-the-scenes look at how drug policies are actually made, identifies some of the challenges for researchers in doing policy advocacy, and provides concrete tools for researchers to effectively engage in transforming policies.
Julie Netherland, PhD, is the Director of the Office of Academic Engagement for the Drug Policy Alliance. In that role, she advances drug policy reform by supporting scholars in doing advocacy, convening experts from a range of disciplines to inform the field, and strengthening DPA’s use of research and scholarship in developing and advancing its policy positions.
Dr. Netherland previously served as the Deputy State Director of DPA’s New York Policy Office, where she was instrumental in passing two laws to legalize the use of medical marijuana in New York and advancing a number of harm reduction and public health approaches to drug policy. Dr. Netherland is the editor of Critical Perspectives on Addiction (Emerald Press, 2012). She holds a PhD in sociology from the City University of New York Graduate Center, a Masters in Social Work from Boston University, and B.A. from Bryn Mawr College. She teaches at John Jay College of Criminal Justice and is a social work field instructor for Columbia University.
Presented by: Arthur Caplan, PhD
Presentation title: Expanded Access, Ethics and Compassionate Use - From Drugs for HIV to Personalized Medicine
Arthur Caplan is the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Bioethics at New York University Langone Medical Center. He is the co-founder and Dean of Research of the NYU Sports and Society Program and the head of the ethics program in the Global Institute for Public Health at NYU.
Dr. Caplan is the author or editor of thirty-five books and over 700 papers in peer reviewed journals. He is a regular commentator on bioethics and health care issues for WebMD/Medscape, for WGBH radio in Boston and WMNF public radio in Tampa. He appears frequently as a guest and commentator on various other national and international media outlets.
Dr. Caplan is the recipient of many awards and honors including:
- McGovern Medal of the American Medical Writers Association
- Franklin Award from the City of Philadelphia
- In 2001, Person of the Year, USA Today
- In 2008, one of the ten most influential people in science by Discover magazine
- One of the fifty most influential people in American health care by Modern Health Care magazine
- One of the ten most influential people in America in biotechnology by the National Journal
- One of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology
- One of the 100 most influential people in biotechnology by Scientific American magazine
- In 2011, Patricia Price Browne Prize in Biomedical Ethics
- In 2014, the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States
- In 2016, the National Organization for Rare Disorders (NORD) honored him with their ‘Rare Impact Award’